VANGUARD GROUP INC 13D and 13G filings for Reata Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | Reata Pharmaceuticals, Inc. RETA | VANGUARD GROUP INC | 2,705,656 8.530% | 147,983 (+5.79%) | Filing |
| 2022-02-10 08:32 am Purchase | 2021-12-31 | 13G | Reata Pharmaceuticals, Inc. RETA | VANGUARD GROUP INC | 2,557,673 8.130% | 237,642 (+10.24%) | Filing |
| 2021-02-10 11:47 am Purchase | 2020-12-31 | 13G | Reata Pharmaceuticals, Inc. RETA | VANGUARD GROUP INC | 2,320,031 7.470% | 153,145 (+7.07%) | Filing |